Key result
In patients with chronic constipation, elobixibat daily resulted in less frequent adverse events compared to lubiprostone daily over 2 weeks.
Why the study?
Does elobixibat improve bowel symptoms and reduce adverse events compared to lubiprostone in patients with chronic constipation?
Cohort (n=1,887)
No
Does elobixibat improve bowel symptoms and reduce adverse events compared to lubiprostone in patients with chronic constipation?
Elobixibat is a safe and beneficial treatment for mildly symptomatic chronic constipation, offering fewer adverse events like nausea compared to lubiprostone, though with slightly less improvement in stool consistency.
Answers are grounded in this paper and cite their sources.
May be associated with fewer adverse events than lubiprostone; hypothesis-generating and should not yet change practice.
INTRODUCTION: Elobixibat is a new laxative, but its efficacy and adverse events (AEs) are insufficiently examined compared with those of other laxatives. Hence, by propensity score (PS) matching, we compared the effects and AEs between elobixibat and lubiprostone. METHODS: We retrospectively analyzed 1,887 Japanese patients with chronic constipation (CC) treated at our hospital between October 2013 and April 2020. Enrolled patients were divided into three treatment groups, namely, elobixibat (10 mg daily) (E10 group, n = 293), lubiprostone (24 μg daily) (L24 group, n = 772), and lubiprostone (48 μg daily) (L48 group, n = 822), as their first treatment. We then investigated the changes on the weekly average number of spontaneous bowel movements, stool consistency scores (SCSs), and AEs starting from the baseline until the end of the 2-week treatment. To adjust for patients' background, we performed one-to-one nearest neighbor matching without replacement between elobixibat- and lubiprostone-treated patients according to the individual estimated PSs. RESULTS: After treatment, for SCSs, both the L24 and L48 groups significantly improved compared with the E10 group (p < 0.05), but their stools were soft (Bristol Stool Form Scale: 4.8). Notably, the E10 group had less frequent AEs than the L24 group (26 [9.0%] vs. 43 [14.8%], p = 0.03). Particularly, nausea was significantly less in the E10 group than that in the L48 group (2 [0.7%] vs. 7 [2.4%], p = 0.01). CONCLUSION: Elobixibat is a beneficial drug for patients with mildly symptomatic CC and is safe to use, given its few AEs.
No takes yet. Share an insight, caveat, or question.
Eguchi et al. (2020) conducted a cohort in Chronic constipation (n=1,887). Elobixibat vs. Lubiprostone (24 μg or 48 μg daily) was evaluated on Changes on the weekly average number of spontaneous bowel movements, stool consistency scores (SCSs), and adverse events (AEs) (p=0.03). In patients with chronic constipation, elobixibat daily resulted in less frequent adverse events compared to lubiprostone daily over 2 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: